Insider Trading & Ownership of Versant Venture Capital VI, L.P.

Location
San Francisco, CA
Summary
The estimated value of insider holdings of Versant Venture Capital VI, L.P. is at least $196,878,133 dollars as of 02 Oct 2025. Versant Venture Capital VI, L.P. is the 10%+ Owner of LENZ Therapeutics, Inc. and owns shares of LENZ Therapeutics, Inc. (LENZ) stock worth about $85.32M. Versant Venture Capital VI, L.P. is the 10%+ Owner of Monte Rosa Therapeutics, Inc. and owns shares of Monte Rosa Therapeutics, Inc. (GLUE) stock worth about $53.19M. Versant Venture Capital VI, L.P. is the 10%+ Owner of Black Diamond Therapeutics, Inc. and owns shares of Black Diamond Therapeutics, Inc. (BDTX) stock worth about $28.75M. Versant Venture Capital VI, L.P. is the 10%+ Owner of Century Therapeutics, Inc. and owns shares of Century Therapeutics, Inc. (IPSC) stock worth about $18.13M. Versant Venture Capital VI, L.P. is the 10%+ Owner of Contineum Therapeutics, Inc. and owns shares of Contineum Therapeutics, Inc. (CTNM) stock worth about $8.93M. Versant Venture Capital VI, L.P. is the 10%+ Owner of Tempest Therapeutics, Inc. and owns shares of Tempest Therapeutics, Inc. (TPST) stock worth about $2.56M.
Signature
Versant Vantage II, LP By: Versant Vantage II GP, L.P. Its: General Partner By: Versant Vantage II GP-GP, LLC Its: General Partner By: /s/ Max Eisenberg Its: Chief Operating Officer
All Insider Reports
All Insider Reports

Notify me when Versant Venture Capital VI, L.P. files a new Insider Trading report.

⭐ Subscribe ⭐

Ownership of Versant Venture Capital VI, L.P.

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
LENZ LENZ Therapeutics, Inc. 10%+ Owner $85,316,256 -$66,603,139 -44% 30 Sep 2025
GLUE Monte Rosa Therapeutics, Inc. 10%+ Owner $53,192,865 28 Oct 2024
BDTX Black Diamond Therapeutics, Inc. 10%+ Owner $28,747,309 28 Aug 2024
IPSC Century Therapeutics, Inc. 10%+ Owner $18,127,503 09 Aug 2022
CTNM Contineum Therapeutics, Inc. 10%+ Owner $8,931,592 09 Apr 2024
TPST Tempest Therapeutics, Inc. 10%+ Owner $2,562,608 08 Aug 2024
LVTX LAVA Therapeutics NV 10%+ Owner $0 -$6,571,090 -100% 19 Sep 2025
OYST Oyster Point Pharma, Inc. 10%+ Owner 03 Jan 2023

Insider Transactions Reported by Versant Venture Capital VI, L.P.:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.